Treatment of bone loss and changes in bone architecture in osteopenic patients with Crohn's disease; a comparison between calcium supplementation and vitamin D alone or combined with oral Risedronate 35 mg once weekly

Trial Profile

Treatment of bone loss and changes in bone architecture in osteopenic patients with Crohn's disease; a comparison between calcium supplementation and vitamin D alone or combined with oral Risedronate 35 mg once weekly

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Risedronic acid (Primary) ; Calcium/colecalciferol
  • Indications Bone resorption; Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Sanofi; Warner Chilcott
  • Most Recent Events

    • 30 Mar 2014 Integrated data from the ISRCTN trial record.
    • 30 Mar 2014 Integrated data from the Netherlands Trial Register record.
    • 30 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top